RGNX
NASDAQ · Biotechnology
Regenxbio Inc
$7.38
-0.33 (-4.28%)
Financial Highlights (FY 2026)
Revenue
227.32M
Net Income
-258,580,903
Gross Margin
88.1%
Profit Margin
-113.8%
Rev Growth
+14.8%
D/E Ratio
1.82
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.1% | 88.1% | 65.6% | 65.6% |
| Operating Margin | -94.6% | -85.1% | 22.7% | 23.0% |
| Profit Margin | -113.8% | -108.1% | 16.1% | 20.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 227.32M | 198.05M | 81.92M | 77.44M |
| Gross Profit | 200.24M | 174.46M | 53.74M | 50.80M |
| Operating Income | -214,997,769 | -168,581,627 | 18.58M | 17.83M |
| Net Income | -258,580,903 | -202,755,543 | 13.19M | 16.19M |
| Gross Margin | 88.1% | 88.1% | 65.6% | 65.6% |
| Operating Margin | -94.6% | -85.1% | 22.7% | 23.0% |
| Profit Margin | -113.8% | -108.1% | 16.1% | 20.9% |
| Rev Growth | +14.8% | +14.8% | +8.8% | +5.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 163.82M | 163.82M | 100.32M | 116.10M |
| Total Equity | 89.99M | 89.99M | 233.09M | 229.51M |
| D/E Ratio | 1.82 | 1.82 | 0.43 | 0.51 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -194,171,263 | -160,709,792 | 28.49M | 26.62M |
| Free Cash Flow | — | — | 20.59M | 19.17M |